Crystal structure of KRAS A146T-GDP demonstrating open switch 1 conformation

Experimental Data Snapshot

  • Resolution: 1.40 Å
  • R-Value Free: 0.145 
  • R-Value Work: 0.112 
  • R-Value Observed: 0.113 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Tissue-Specific Oncogenic Activity of KRASA146T.

Poulin, E.J.Bera, A.K.Lu, J.Lin, Y.J.Strasser, S.D.Paulo, J.A.Huang, T.Q.Morales, C.Yan, W.Cook, J.Nowak, J.A.Brubaker, D.K.Joughin, B.A.Johnson, C.W.DeStefanis, R.A.Ghazi, P.C.Gondi, S.Wales, T.E.Iacob, R.E.Bogdanova, L.Gierut, J.J.Li, Y.Engen, J.R.Perez-Mancera, P.A.Braun, B.S.Gygi, S.P.Lauffenburger, D.A.Westover, K.D.Haigis, K.M.

(2019) Cancer Discov 9: 738-755

  • DOI: https://doi.org/10.1158/2159-8290.CD-18-1220
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRAS G12D , a common mutant form, and KRAS A146T , a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRAS A146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor-induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRAS G12D and KRAS A146T exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS , experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties. See related commentary by Hobbs and Der, p. 696 . This article is highlighted in the In This Issue feature, p. 681 .

  • Organizational Affiliation

    Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
GTPase KRas
A, B
168Homo sapiensMutation(s): 1 
UniProt & NIH Common Fund Data Resources
Find proteins for P01116 (Homo sapiens)
Explore P01116 
Go to UniProtKB:  P01116
PHAROS:  P01116
GTEx:  ENSG00000133703 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP01116
Sequence Annotations
  • Reference Sequence
Small Molecules
Experimental Data & Validation

Experimental Data

  • Resolution: 1.40 Å
  • R-Value Free: 0.145 
  • R-Value Work: 0.112 
  • R-Value Observed: 0.113 
  • Space Group: P 3
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 78.024α = 90
b = 78.024β = 90
c = 55.863γ = 120
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
HKL-2000data reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2019-05-22
    Type: Initial release
  • Version 1.1: 2019-06-19
    Changes: Data collection, Database references, Structure summary
  • Version 1.2: 2023-10-04
    Changes: Data collection, Database references, Refinement description